Skip to main content

Table 2 Demographics of the study populations

From: Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks

  COMPACT study
C1-INH(SC)
60 IU/kg
(N = 45)
CHANGE study
C1-INH(IV)
1000 U
(N = 22)
Age, y
 Mean (SD) 36.8 (14.9) 38.1 (17.2)
 Median (range) 35.0 (14, 72) 38.5 (9, 73)
Gender, n (%)
 Female 32 (71.1) 20 (90.9)
 Male 13 (28.9) 2 (9.1)
Race, n (%)
 White 44 (97.8) 21 (95.5)
 Black/African-American 1 (2.2) 1 (4.5)
 Asian 0 0
 Other 0 0
Weight, kg
 Mean (SD) 80.2 (24.6) 73.4 (18.9)
 Median (range) 78.0 (43.0, 156.8) 69.3 (37.6, 113.9)
HAE type, n (%)
 Type 1 37 (82.2) 18 (81.8)
 Type 2 8 (17.8) 4 (18.2)
  1. HAE hereditary angioedema, IU international units, IV intravenous, SC subcutaneous, SD standard deviation, U units, y years